Zymeworks and BeiGene plan to initiate registration-enabling global studies with ZW25 in HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA).
The plans are based on new data obtained from a Phase I clinical trial performed in heavily pretreated patients with HER2‑expressing solid tumours.
Go deeper with GlobalData
Based on Zymeworks’ Azymetric platform, ZW25 concurrently binds to two non-overlapping epitopes of HER2, resulting in several mechanisms of action.
Zymeworks is developing the drug to treat solid tumours that express HER2.
The ongoing, three-part Phase I trial assessed the safety, tolerability and effectiveness of ZW25 as a monotherapy and in combination with chemotherapy agents in patients with locally advanced and/or metastatic HER2-expressing cancers.
Data was obtained from 69 patients, except those with breast cancer, treated with 10mg/kg weekly or 20mg/kg every other week dose. At the data cut-off time, 57 of these patients were response evaluable.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOverall disease control rate was 70%, including 44% partial responses and 26% with stable disease. Results showed that 32% of patients achieved disease control for more than six months.
According to the company, nine evaluable patients with BTC experienced a DCR of 78% and an objective response rate (ORR) of 67%.
In addition, 13 patients with colorectal cancer and 23 with GEA had 46% and 39% ORRs, respectively.
Zymeworks added that the confirmed responses were observed across patients with other cancers, including a 100% reduction in target lesions in those with pancreatic cancer.
The overall median progression-free survival was 5.5 months and is said to be evolving.
Further analysis showed that the drug candidate was well-tolerated, with the most common adverse events being diarrhoea, infusion-related reaction and nausea.
BeiGene co-founder, CEO and chairman John Oyler said: “The encouraging clinical data on ZW25 supports further evaluation of this bispecific antibody in HER2-expressing solid tumours.”
ZW25 received fast track status in the US for first-line gastroesophageal adenocarcinoma in combination with standard of care chemotherapy, and orphan drug designation for gastric and ovarian cancers.
